Top

Gepubliceerd in:

01-10-2008 | Artikelen

Langetermijnuitkomsten na hydrocortisonbehandeling voor chronische longziekte bij prematuur geboren kinderen

Auteurs: K. J. Rademaker, F. Groenendaal, L. S. de Vries, F. van Bel

Gepubliceerd in: Tijdschrift voor Kindergeneeskunde | Uitgave 5/2008

Samenvatting

Het gebruik van postnatale corticosteroïden voor de preventie of behandeling van chronische longziekte bij pasgeborenen blijft een punt van discussie. Dexamethason kent vele negatieve bijwerkingen. Hydrocortison zou een alternatief kunnen zijn indien het even effectief is en minder nadelige effecten op de lange termijn veroorzaakt. Dit artikel geeft een overzicht van de tot nu toe gepubliceerde studies betreffende de behandeling met hydrocortison in de neonatale periode in relatie tot de langetermijnuitkomsten op de neuromotorische ontwikkeling.

vorige artikel Verkleving van de labia minora

volgende artikel Primair pompen bij peuters: start insulinepomptherapie bij diagnose

Committee on Obstetric Practice. ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol. 2002;99(5 Pt 1):871-3.

Barrington KJ. Hazards of systemic steroids for ventilator-dependent preterm infants: what would a parent want? CMAJ 2001;165(1):33-4.

Thebaud B, Lacaze-Masmonteil T, Watterberg K. Postnatal glucocorticoids in very preterm infants: `the good, the bad, and the ugly'? Pediatrics. 2001;107:413-5.

Finer NN, Craft A, Vaucher YE, et al. Postnatal steroids: short-term gain, long-term pain? J Pediatr. 2000;137:9-13.

Jobe AH. Postnatal corticosteroids for preterm infants – do what we say, not what we do. N Engl J Med. 2004;350:1349-51.

Shinwell ES. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol Neonate. 2003;84:96-100.

Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1:1356-8.

Hack M, Fanaroff AA. Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev. 1999;53:193-218.

Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:E7.

10.

O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104(1 Pt 1):15-21.

11.

Shinwell ES, Karplus M, Bader D, et al. Neonatologists are using much less dexamethasone. Arch Dis Child Fetal Neonatal Ed. 2003;88:F432-3.

12.

Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109: 330-8.

13.

Finer NN, Powers RJ, Ou CH, et al. Prospective evaluation of postnatal steroid administration: a 1-year experience from the California Perinatal Quality Care Collaborative. Pediatrics. 2006;117: 704-13.

14.

Short EJ, Klein NK, Lewis BA, et al. Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics. 2003;112:e359.

15.

Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304-13.

16.

Parikh NA, Lasky RE, Kennedy KA, et al. Postnatal dexamethasone therapy and cerebral tissue volumes in extremely low birth weight infants. Pediatrics. 2007;119:265-72.

17.

Baden M, Bauer CR, Colle E, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics. 1972; 50:526-34.

18.

Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999;104:1258-63.

19.

Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics. 1995;95:120-5.

20.

Heide-Jalving M van der, Kamphuis PJ, Laan MJ van der, et al. Short- and long-term effects of neonatal glucocorticoid therapy: is hydrocortisone an alternative to dexamethasone? Acta Paediatr. 2003;92:827-35.

21.

Watterberg KL, Gerdes JS, Cole CH, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics. 2004;114:1649-57.

22.

Peltoniemi O, Kari MA, Heinonen K, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. J Pediatr. 2005;146:632-7.

23.

Bonsante F, Latorre G, Iacobelli S, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology. 2007;91:217-21.

24.

Taeusch HW Jr, Wang NS, Baden N, et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathology. Pediatrics. 1973;52:850-4.

25.

Watterberg KL, Shaffer ML, Mishefske MJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics. 2007; 120:40-8.

26.

Lodygensky GA, Rademaker K, Zimine S, et al. Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics. 2005;116:1-7.

27.

Rademaker KJ, Rijpert M, Uiterwaal CS, et al. Neonatal hydrocortisone treatment related to 1H-MRS of the hippocampus and short-term memory at school age in preterm born children. Pediatr Res. 2006;59:309-13.

28.

Rademaker KJ, Uiterwaal CS, Groenendaal F, et al. Neonatal hydrocortisone treatment: neurodevelopmental outcome and MRI at school age in preterm-born children. J Pediatr. 2007;150:351-7.

29.

Karemaker R, Heijnen CJ, Veen S, et al. Differences in behavioral outcome and motor development at school age after neonatal treatment for chronic lung disease with dexamethasone versus hydrocortisone. Pediatr Res. 2006;60:745-50.

30.

Kloet ER de, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev. 1998;19:269-301.

31.

Sapolsky RM, Uno H, Rebert CS, Finch CE. Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci. 1990;10:2897-902.

32.

Uno H, Tarara R, Else JG, et al. Hippocampal damage associated with prolonged and fatal stress in primates. J Neurosci. 1989;9:1705-11.

33.

Huang CC, Lin HR, Liang YC, Hsu KS. Effects of neonatal corticosteroid treatment on hippocampal synaptic function. Pediatr Res. 2007;62:267-70.

34.

Almeida OF, Conde GL, Crochemore C, et al. Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J. 2000;14:779-90.

35.

Holmes MC, Seckl JR. The role of 11beta-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol. 2006;248:9-14.

36.

Holmes MC, Sangra M, French KL, et al. 11beta-hydroxysteroid dehydrogenase type 2 protects the neonatal cerebellum from deleterious effects of glucocorticoids. Neuroscience. 2006;137:865-73.

37.

Taketomo CK, Hodding JH, Kraus D (eds.). Pediatric dosage handbook, 11th ed. Lexicomp, 2004.

38.

Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem. 1998;71: 2431-8.

39.

Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001;50:706-11.

40.

Caeymaex L, Gatel P, Castel C, et al. Low-dose hydrocortisone alone does not lead to gastro-intestinal perforation in ELBW infants. SPR, 2006.

41.

Hallman M, Peltoniemi O, Saarela T. Early neonatal hydrocortisone: study rather than treat. Pediatrics. 2006;118:2540-2.

42.

Ramanathan R, Siassi B, Sardesai S, deLemos R. Dexamethasone versus hydrocortisone for hypotension refractory to high dose inotropic agents and incidence of candida infection in extremely low birth weight infants. Pediatr Res. 2006;39: 240.

43.

Botas CM, Kurlat I, Young SM, Sola A. Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics. 1995;95: 883-7.

44.

Ng PC, Lee CH, Bnur FL, et al. A double-blind, randomized, controlled study of a `stress dose' of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics. 2006; 117:367-75.

45.

Eichenwald EC, Stark AR. Are postnatal steroids ever justified to treat severe bronchopulmonary dysplasia? Arch Dis Child Fetal Neonatal Ed. 2007;92:F334-7.

46.

Doyle LW, Davis PG, Morley CJ, et al. Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics. 2006;117:75-83

Titel: Langetermijnuitkomsten na hydrocortisonbehandeling voor chronische longziekte bij prematuur geboren kinderen
Auteurs: K. J. Rademaker
F. Groenendaal
L. S. de Vries
F. van Bel
Publicatiedatum: 01-10-2008
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Tijdschrift voor Kindergeneeskunde / Uitgave 5/2008
Print ISSN: 0376-7442
Elektronisch ISSN: 1875-6840
DOI: https://doi.org/10.1007/BF03078212

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 5/2008

Primair pompen bij peuters: start insulinepomptherapie bij diagnose

Internationale wetenschappelijke publicaties op het gebied van de neonatologie in Nederland in de periode 2004-2006

Negende Symposium Neonatale Neurologie van de Nederlands-Vlaamse Werkgroep Neonatale Neurologie

Neonatale reanimatievaardigheden van arts-assistenten kindergeneeskunde

Neonatale reanimatie

Neonatale reanimatie: Zijn eerstejaars arts-assistenten kindergeneeskunde (on)voldoende voorbereid?